Treprostinil(CAS: 81846-19-7)

Treprostinil (CAS: 81846-19-7) is subject to regulatory guidelines including GHS classification for health hazards, REACH regulations for the registration, evaluation, authorization, and restriction of chemicals, and FDA/EPA requirements for pharmaceutical and environmental safety. It is classified as a vasoactive drug in the United States and requires specific handling and storage conditions to ensure safety and efficacy.

Alternatives to Treprostinil (CAS: 81846-19-7) in synthesis include analogs such as iloprost and trexinal, which share similar structural features and pharmacological properties. Common alternative reagents and methods include the use of ketone reduction and nitrite addition to form the prostacyclin ring structure, offering various synthetic routes for this compound.

The market for Treprostinil (CAS: 81846-19-7) is focused on its use as a vasodilator in the treatment of pulmonary arterial hypertension. Research trends include the development of its prodrug forms, such as selexipag, and the exploration of new formulations to improve patient compliance and efficacy. Additionally, there is ongoing interest in understanding the mechanisms of action and identifying potential off-label applications.

Waste containing Treprostinil (CAS: 81846-19-7) should be handled with care to prevent environmental contamination and ensure safety. Collection should be done in designated containers, and the waste should be neutralized and incinerated or disposed of by a professional hazardous waste disposal service. Proper personal protective equipment and disposal methods should be used to prevent exposure and maintain environmental standards.